Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7657166 | 0.75 | PLK4 (0.43) | — | |
| SCHEMBL4000656 | 0.72 | — | — | |
| SCHEMBL4003340 | 0.69 | MAPK10 (0.41) | EGFR | |
| SCHEMBL1391792 | 0.69 | NFKB1 (0.33) | — | |
| SCHEMBL1147539 | 0.68 | — | — | |
| SCHEMBL2500797 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL5752769 | 0.68 | EGFR (0.39) | EGFR | |
| SCHEMBL3999919 | 0.67 | MEN1 (0.31) | — | |
| SCHEMBL4470661 | 0.67 | MAP3K12 (0.31) | — | |
| SCHEMBL1012368 | 0.67 | CYP2D6 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | claimed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | claimed |
| EP-1709045-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2006-10-11 | — | — | EP | claimed |
| US-20050171141-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-04 | — | — | US | claimed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | claimed |
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1709045-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050171141-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-04 | — | — | US | disclosed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171141-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | EGFR 2070/4885 |
| US-20090042928-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | EGFR 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.